| Home : October 02 2018 Computer News : Office of Generic Drugs (OGD/FDA) Awards $1M FDA Contract to CUBRC and EpiVax for Demonstration and Validation of Immunogenicity Risk Assessment Methods for Generic Peptide Drugs and Their Impurities |
|
Office of Generic Drugs (OGD/FDA) Awards $1M FDA Contract to CUBRC and EpiVax for Demonstration and Validation of Immunogenicity Risk Assessment Methods for Generic Peptide Drugs and Their Impurities |
October 02, 2018
PROVIDENCE, R.I., Oct. 2, 2018 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announced today that they have been awarded a two-year $1 million contract from the Food and Drug Administration (FDA) in response to a Broad Agency Announcement (BAA), FDA BAA-17-00123. The...
Link: https://www.prnewswire.com:443/news-releases/office-of-generic-drugs-ogdfda-awards-1m-fda-contract-to-cubrc-and-epivax-for-demonstration-and-validation-of-immunogenicity-risk-assessment-methods-for-generic-peptide-drugs-and-their-impurities-300722178.html
|
|
|
|
|
